Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Clin Cases. May 16, 2018; 6(5): 74-83
Published online May 16, 2018. doi: 10.12998/wjcc.v6.i5.74
Table 2 Univariate analysis of all patients for overall survival
Characteristicn (%)mOS (mo)95%CIP valueχ2
Gender
Male42 (62.7)33.428.03-38.770.6590.195
Female25 (37.3)35.230.40-40.00
Age (yr)
≥ 5726 (38.8)33.029.34-36.660.1781.818
< 5741 (61.2)35.232.58-37.82
Child-Pugh
A44 (65.7)35.231.00-39.400.00017.805
B23 (34.3)21.016.22-25.78
Tumor diameter (cm)
≥ 624 (35.8)20.014.51-25.490.0165.815
< 643 (64.2)35.232.63-37.77
Serum albumin (g/L)
≥ 3536 (53.7)36.033.34-38.660.0663.39
< 3531 (46.3)23.018.25-27.75
Serum bilirubin (umol/L)
≥ 2019 (28.4)24.018.27-29.730.0067.612
< 2048 (71.6)35.032.52-37.48
LDH (U/L)
≥ 24539 (58.2)28.024.83-31.170.1432.143
< 24528 (41.8)33.031.19-34.81
AFP (ng/mL)
≥ 20044 (65.7)28.020.50-35.500.0116.448
< 20023 (34.3)32.025.86-38.14
Number of TACE
≥ 233 (49.3)29.823.14-36.460.0793.809
< 234 (50.7)36.635.12-38.08
Sorafenib + TACE38 (56.7)35.230.02-40.380.00012.645
TACE29 (43.3)22.021.23-22.77